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Abstract
Introduction In the USA, Food and Drug Administration
regulations prohibit the sale of flavoured cigarettes,
with menthol being the exception. However, the
manufacture, advertisement and sale of flavoured cigar
products are permitted. Such flavourings influence
positive perceptions of tobacco products and are linked
to increased use. Flavourings may mask the taste of
tobacco and enhance smoke inhalation, influencing
toxicant exposure and abuse liability among novice
tobacco users. Using clinical laboratory methods, this
study investigates how flavour availability affects
measures of abuse liability in young adult cigarette
smokers. The specific aims are to evaluate the effect of
cigar flavours on nicotine exposure, and behavioural and
subjective measures of abuse liability.
Methods and analyses Participants (projected n=25) are
healthy smokers of five or more cigarettes per day over the
past 3 months, 18–25 years old, naive to cigar use (lifetime
use of 50 or fewer cigar products and no more than 10
cigars smoked in the past 30 days) and without a desire
to quit cigarette smoking in the next 30 days. Participants
complete five laboratory sessions in a Latin square
design with either their own brand cigarette or a sessionspecific Black & Mild cigar differing in flavour (apple,
cream, original and wine). Participants are single-blinded
to cigar flavours. Each session consists of two 10-puff
smoking bouts (30 s interpuff interval) separated by 1 hour.
Primary outcomes include saliva nicotine concentration,
behavioural economic task performance and response to
various questionnaire items assessing subjective effects
predictive of abuse liability. Differences in outcomes
across own brand cigarette and flavoured cigar conditions
will be tested using linear mixed models.
Ethics and dissemination The Virginia Commonwealth
University Institutional Review Board approved the study
(VCU IRB: HM20007848). Dissemination channels for study
findings include scientific journals, scientific meetings, and
policy briefs.
Trial registration number NCT02937051.

Strengths and limitations of this study
►► This study will provide the opportunity to examine

the abuse liability across flavours of one of the
most popular cigar brands in a population that is
at increased risk of harm from flavoured tobacco
products.
►► The study triangulates abuse liability assessment
in a clinical laboratory setting using physiological,
behavioural and subjective measures.
►► Use of behavioural economic tasks to measure
abuse liability for cigars represents a novel approach to understand this tobacco product type.
►► As this study is being conducted in a controlled setting at a single site, results may not generalise to
other use conditions/settings or among other populations/geographic regions.

Introduction
In 2009, the US Food and Drug Administration (FDA) banned cigarettes with characterising flavours (except for menthol1), given
their appeal to youth.2 Five years later, the
FDA proposed broader regulatory authority
over cigars but did not restrict the availability
of flavoured cigars.3 However, in March 2018,
an Advanced Notice of Proposed Rulemaking
was issued by the FDA, in which commentary
and research are sought to inform the regulation of flavours in tobacco products including
cigars.4 These ongoing changes in tobacco
regulation and the evolution of the tobacco
marketplace highlight the need for empirical evidence regarding the use and appeal of
cigar products and their associated flavours.
The availability of flavours for cigars, among
other product characteristics, has been linked
to increased cigar sales5 and consumption.6
These increases are greatest among youth/
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young adults.2 7 8 In 2012–2013, 7.3% of US adults smoked
cigars every day or some days,9 and 12.6% of high school
students reported past month use.10 The vast majority
(nearly 90%) of youth/young adult cigar smokers report
usual brands that offer flavoured varieties.2 Black & Mild
(B&M) is the most popular brand among cigar smokers,
offering at least eight flavoured varieties11 and, accordingly, a much greater proportion of 12–17-year-old cigar
users (51%) prefer B&M compared with those 35 or
older (18%).2 The range of flavoured cigars is vast and
includes flavours that are fruit-like (Apple, Peach), food/
dessert-like (Cream, Dulce de Leche), alcohol-like (Wine,
Double Barrel Rum) and unlike anything normally
associated with gustatory or olfactory sensation (Jazz,
Diamonds)11 12; fruit, sweet/candy and wine are the most
popular flavours.2 13 14 Evidence from tobacco industry
documents and epidemiological work suggests that such
flavour additives are used to promote appeal among
novice users15–17 as well as to mask the taste of tobacco
and enhance smoke inhalation.18 Additionally, a strong
literature supports the role of flavours in influencing positive perceptions, and ultimately use, of tobacco products
including cigars.2 19–22 Flavoured cigar use among youth
is also associated with lower intentions to quit compared
with youth who use non-flavoured tobacco products.23 In
tandem with cigar flavours, factors like marketing and
price may promote initiation and continued use.7 17 24
For example, B&Ms are defined by weight (more than
3 lbs/1000) in the USA as large cigars via tax guidelines11 and thus are much cheaper than some other cigar
subtypes. Together, these factors combine to make cigars
appealing, suggesting the need to better understand the
extent to which flavours influence the potential for initiation and subsequent use of cigars.
Clinical laboratory methods provide an important means
to understand how flavour may influence tobacco product
use patterns and abuse liability. Generally, abuse liability
is the degree to which a psychoactive drug or formulation
would be used for non-medical purposes and abuse of
that drug would lead to physical or psychological dependence.25 With respect to tobacco products, abuse liability
refers to the likelihood that a given product’s reinforcement value will lead to persistent use and dependence.26
The clinical laboratory setting allows for systematic, efficient assessment of physiological effects (eg, nicotine and
toxicant exposure, cardiovascular response), behavioural
choice tasks and subjective responses,27 all of which are
important for predicting tobacco use patterns including
the likelihood for progression to regular use, potential
for harm28 and abuse liability.24–26 For example, among
regular B&M cigar smokers, completing two 10-puff bouts
of an active (lit) B&M yielded significantly greater nicotine exposure, heart rate, expired air carbon monoxide
(CO) and positive subjective effects compared with two
10-puff bouts of an unlit B&M (sham).29 However, relative
to combustible tobacco cigarettes (CTCs), B&M cigars
appear to deliver less nicotine per puff and produce
higher CO exposure and greater smoke volume in both
2

primarily CTC and primarily cigar smokers.29–32 In terms
of subjective measures, B&Ms may produce acute positive subjective effects (ie, increased ratings of ‘satisfying,’
‘calm you down’) as well as those indicative of drug effects
(increased ratings of ‘dizzy’),29 30 but the only existing
direct comparison of subjective effects between cigarettes
and cigars (performed among dual users of cigarettes
and cigars) suggests that cigarettes are more effective
at reducing the craving to smoke.33 Behavioural choice
tasks such as the cigarette purchase task and multiple
choice procedure assess abuse liability by measuring how
hypothetical or potentially real consumption of tobacco
products changes in response to the price of these products,34–38 providing evidence on how reinforcing these
products are. These behavioural choice tasks have not
been used to assess cigars and, importantly, no studies
have controlled for the influence of cigar flavour on any
of the above outcomes in the clinical laboratory. Flavours
could affect cigar appeal among novice users,15–17 and
increase cigar smoke inhalation,18 leading to increased
nicotine exposure and subsequent continued use. As
previous work from our team39 and others40 41 supports,
simultaneously assessing physiological, behavioural and
subjective measures in the clinical laboratory allows efficient and cost-effective testing of all of these hypotheses.
Considering the current tobacco marketplace and
increasing rates of cigar use among vulnerable populations,2 7 8 evaluating the effects of cigar flavours on
abuse liability is essential to protecting public health
and informing FDA regulation of cigars. Clinical laboratory methods are uniquely suited to measure the effects
of cigar flavours on abuse liability by using a controlled
setting to provide much-needed data. Our research uses
an innovative approach and includes key advances to
improve our understanding of how cigar flavours may
influence use. These innovations include: (1) testing
the most popular cigar brand and flavours, (2) triangulating abuse liability in the laboratory using physiological,
behavioural and subjective measures and (3) purposeful
accrual of a population at increased risk of harm from
flavoured cigar products (ie, young adult cigarette
smokers). The specific aims of the study are to evaluate
the effect of cigar flavours on (1) nicotine exposure, (2)
behavioural measures of abuse liability and (3) subjective
measures of abuse liability.

Methods and analyses
Patient and public involvement
Neither patients nor the public were involved in the formulation of research questions, outcome measures, experimental design, recruitment or conduct of the study. Results
from the study, as well as additional information about the
study, will be provided to participants on request.
Study design
This study involves 25 current young adult cigarette
smokers who complete five Latin square ordered,
Wall CS, et al. BMJ Open 2018;8:e023850. doi:10.1136/bmjopen-2018-023850
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within-subject laboratory conditions that differ by the
tobacco product used: (1) own brand cigarette (positive
control), (2) original-flavoured B&M cigar, (3) apple-flavoured B&M cigar, (4) cream-flavoured B&M cigar and
(5) wine-flavoured B&M cigar. The study takes place in
a clinical laboratory setting at Virginia Commonwealth
University (VCU). VCU is a diverse, urban campus located
in Richmond, Virginia, USA.

injury, sensitivity reaction or any other illness or condition occurring while a participant is in the study. Participants are also permitted to self-withdraw from the study
at any point. If they chose to remove themselves from the
study, they will receive no future contact from the study
site. All participants who are withdrawn at any point, for
any reason, will be replaced until a total of 25 participants
have completed the study.

Study population
The study population is young adult (18–25 years old)
cigarette smokers from the greater Richmond area who
report little to no experience with cigars, cigarillos or
little cigars (naive; smoked no more than 50 cigar products of any type in lifetime with no more than 10 cigars
in the past 30 days) and who are not planning to quit
smoking cigarettes in the next 30 days.

Recruitment and enrolment
Interested individuals identify themselves by responding
to institutional review board (IRB)-approved advertisements for cigarette smoking research studies. Participants
are recruited via in-person recruitment, websites, message
boards, print advertisements, web-based advertisements
(eg, 
craigslist.
org) and approved tobacco study registries. Participants begin by completing a survey, either by
phone or online, to assess eligibility. Participants also are
provided the opportunity to consent to joining a registry,
and, should they consent, any answers that are provided
are maintained for future contact purposes. If a participant is deemed potentially eligible, they are invited into
the laboratory to undergo an in-person screening visit
that includes administration of informed consent procedures and assessment of additional eligibility criteria. The
study is explained fully to the potential participant, and,
after being provided adequate time to read the information and ask questions, participants are asked to sign and
date the informed consent document.
Following consent, participant eligibility is confirmed
via a baseline questionnaire. Participants are also asked to
provide a urine sample, which is used to test for cotinine
levels to verify smoking status and, for women, to test for
pregnancy. Additional physiological data are collected
from participants for eligibility and baseline assessment
purposes (ie, height, weight, baseline BP, baseline HR and
expired breath CO levels). Following review of all baseline information, eligible participants are then enrolled
into the study.

Inclusion criteria
To be included, participants must be healthy, as determined by self-report and by measured heart rate/blood
pressure (HR/BP), ages 18–25 and willing to provide
informed consent. They must agree to attend laboratory
sessions and abstain from tobacco/nicotine as required,
to use the designated products and to follow the study
protocol. Participants are regular cigarette smokers
(≥5 cigarettes/day for the past 3 months) naive to cigar
products, who provide a semiquantitative urine cotinine
result of ≥3 (100–200 ng/mL) at screening (NicAlert test;
Jant Pharmacal Corporation, Encino, Los Angeles, California, USA).
Exclusion criteria
Individuals with a self-reported history of chronic diseases
or psychiatric conditions are excluded. A chronic disease
in this study is defined as any chronic medical condition
that an individual has had for 3 or more months. Other
exclusion criteria are: history of or active cardiovascular
disease, current oral health problems or injuries, low/
high BP (self-reported or confirmed during screening),
seizures or other medical conditions/allergies that may
interact with study conditions. Use of regular prescription medication (other than vitamins or birth control)
and past-month use of cocaine, opioids, benzodiazepines
and methamphetamine (self-report) are exclusionary.
Individuals who report using cannabis or alcohol on >20
of the past 30 days also are excluded. Women who report
breastfeeding or test positive for pregnancy (by urinalysis) at screening are excluded.
Withdrawal criteria
If a participant fails to comply with the study protocol
prior to or during one session, they are offered the opportunity to repeat the condition once. Failure to comply a
second time is ground for withdrawal by the principal
investigator (PI). Additionally, participants who experience adverse health effects are considered for withdrawal
following consultation with the study’s medical monitor.
Possible adverse health effects include any side effect,
Wall CS, et al. BMJ Open 2018;8:e023850. doi:10.1136/bmjopen-2018-023850

Condition assignment and materials
After enrolment, eligible participants are assigned a
condition order and scheduled for the first of five sessions.
Participants attend one session for each of the five conditions, each occurring at least 48 hours apart. Condition
orders are counterbalanced using a Latin square to
help control for carryover effects. The Latin square was
created in advance, reviewed by the study statistician for
accuracy and is stored in a secure, password-protected
database that is only accessible to study staff. The study
staff are unblinded to condition orders and prepare the
appropriate session product prior to each session. Participants are blind to the flavour assignment for B&M conditions. The own brand cigarette session is not blinded, as
the product visibly differs from cigars.
Four flavours of plastic-tipped B&M cigars (John
Middleton, Altria; Richmond, Virginia, USA)—stored
in a dark, dry, temperate location in order to minimise
3
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the possibility of staleness or mould—are used: ‘Apple’,
‘Cream’, ‘Wine’ and ‘Original’. The fifth condition, own
brand cigarette, functions as a positive control. Self-reported own brand cigarettes are purchased locally by
the study staff following enrolment and are stored in a
separate container in the same location as the cigars.
Compensation
Participants are compensated for their time and inconvenience at the end of each session and study compensation is delivered in increasing amounts across sessions
to encourage retention. Participants who complete the
entire study are paid $360 in total (session 1=$50; 2=$60;
3=$70; 4=$80; 5=$100). Participants are provided the
opportunity to receive up to an additional $10.24 during
each session depending on choices made and randomly
chosen for reinforcement during completion of the
behavioural measures.
Measurement instruments
Baseline questionnaire
The baseline survey is a computer-based self-assessment
that includes items regarding demographic characteristics, health history, tobacco use, alcohol use, drug use,
tobacco product harm perceptions, nicotine dependence and time preferences. Demographic characteristics include race/ethnicity, age and employment
status. Health history includes yes/no items assessing
history of or active cardiovascular disease, low/high BP,
seizures, depression, anxiety and other physical health/
psychiatric conditions as well as regular prescription
medication use. Tobacco use items include ever use and
past month use of cigarettes, cigars, hookah, smokeless
tobacco and electronic cigarettes as well as more detailed
measures regarding cigarette smoking behaviour/history
and number of cigar products used in lifetime. Tobacco
product harm perception items were adapted from standardised national surveys.42 43 Nicotine dependence was
assessed using the Fagerstrom Test for Nicotine Dependence.44 Four questions that followed a similar format,
‘Would you rather win/lose $20 now or $30 a year from
now?’, were asked to assess time preference.45
Biological and physiological measures
Before and after each smoking bout (for a total of four
times per session), participants provide saliva samples
using methods and procedures consistent with Salimetrics
‘Passive Drool with Saliva Collection Aid’.46 Saliva samples
are frozen immediately (−80°C) following collection for
later analysis, conducted by a partner laboratory using
previously developed assays.47 Saliva and plasma nicotine
levels have been found to be highly correlated in an examination of exposure via the nicotine patch (r=0.82),48 and
saliva nicotine has been used in acute exposure CTC
paradigms among adolescents with greater exposure
noted among more dependent smokers.49 Further, saliva
assays of nicotine are less invasive and potentially more
sensitive than plasma, as saliva nicotine concentrations
4

are higher relative to plasma.48 50 Secondary physiological
measures include expired air CO concentration, as well
as HR and BP. Expired air CO is assessed via a BreathCO
monitor (Vitalograph, Lenaxa, Kansas, USA). HR/BP
is measured and saved electronically using software and
equipment that also sounds an alarm if safety parameters
are exceeded (Model 506, Criticare Systems).
Behavioural measures
Three behavioural choice tasks (cigarette/cigar purchase
task, cross product purchase task and multiple choice
procedure) are administered at the completion of each
session to assess abuse liability. The cigarette/cigar
purchase task (adapted from Jacobs and Bickel34) is a
hypothetical purchase task wherein participants are asked
how many times they would take 10 puffs of the session
product (cigar or cigarette depending on condition assignment) if they were offered at each of 16 different prices
($0.00, $0.01, $0,02, $0.04, $0.08, $0.16, $0.32, $0.64,
$1.28, $2.56, $3.84, $5.12, $6.40, $7.68, $8.96, $10.24).
This measure has been shown to approximate actual
consumption of addictive substances.51 The cigarette and
cigar purchase tasks produce five outcome measures:
breakpoint, the price at which participants switch from
choosing the tobacco product to choosing money; elasticity (price sensitivity), a measure of how hypothetical
consumption changes in response to changes in price;
intensity, hypothetical consumption at $0 (free); Omax,
the maximum hypothetical expenditure across prices (ie,
the maximum of the product of reported consumption
and price); and Pmax, the price corresponding to Omax.
Breakpoint, intensity, Omax and Pmax will be derived
directly from the data,35 while elasticity will be calculated
using the following equation from Koffarnus et al.52:
−αQo C −1)

k(e
Q
 = Qo × 10



In the equation above, Q is consumption at a given
price, Q0 is consumption at $0 (also known as intensity), α
is elasticity, C is price and k is a constant representing the
span of the data in log10 units. The value of k is typically
set equal to the log10 of the highest reported consumption value minus log10 of the lowest reported consumption value, so we will determine the appropriate k value
once data are collected, but we will also consider other
values of k that provide the best fit for the data as determined by goodness of fit (R2 values) for demand curves.
Cigarette/cigar purchase task data for each participant will be assessed for usability using two of Stein et
al.’s three criteria for non-systematic data identification.53
The two criteria are trend, or whether consumption generally decreases as price increases, and bounce, or whether
there are multiple instances of increases in consumption
between consecutive prices and this jump in consumption exceeds 25% of the original consumption at $0.
Stein et al.’s third criterion, reversals from zero—which
suggests discarding data when any non-zero consumption is reported after two reports of zero consumption
at consecutively increasing prices—will not be used.
Wall CS, et al. BMJ Open 2018;8:e023850. doi:10.1136/bmjopen-2018-023850
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This difference is because our computer-based purchase
task ends the task after two consecutive reports of zero
consumption, so reversals from zero will not be observed.
Data not meeting these criteria will be discarded from
cigarette/cigar purchase task analyses.
The cross-product purchase task is a similar hypothetical purchase task that asks participants how many times
they would purchase 10 puffs from their own brand cigarette at various prices in the same range as described
above when 10 puffs of the session-specific cigar is also
available at a constant price ($1.00); this task is administered only during the four cigar conditions. The crossproduct purchase task produces cross-price elasticity,54 55
defined for each participant as the slope from a regression of log-consumption of cigars (at the fixed price of
$1) on log-cigarette price. A positive value for this slope
would suggest that the flavoured cigar is (at least partially)
substitutable for own brand cigarettes.
The multiple choice procedure involves participants
making choices between tobacco products and various
amounts of money.38 In the current study, this task shows
three columns consisting of 15 different choices: the first
column assigns a choice number to each of the choices,
the second column provides the option of 10 puffs of
the session product and the third offers various amounts
of money in amounts that increase as choice number
increases ($0.01–$10.24; identical to the cigarette/
cigar purchase task except for the lack of $0.00 option).
The participant makes 15 different decisions between
10 puffs of the session product and various amounts of
money. Once the decisions are made, one of these 15
decisions is selected via a random draw of a ball from
an opaque bag; each ball is numbered 1–15 to reflect
one of the numbered choices in the task. If the result of
the randomly selected choice is 10 puffs of the session
product, the participant is given a 10 min consumption
period in which to smoke 10 puffs of the session product
(ad lib), after which the participant undergoes an additional 10 min rest period prior to the end of the session.
If the randomly selected choice is one of the amounts
of money, the participant is given that amount of money
immediately, followed by a 10 min ‘consumption’ period
and a 10 min rest period. The multiple choice procedure
produces the crossover point, measured in US dollars,
which represents the highest price at which participants
chose the tobacco product instead of the money.39 56 57
Data will be excluded for those participants with inconsistent choices (ie, those who switch back from choosing
money to choosing tobacco products at higher prices).
A secondary behavioural measure of smoking
behaviour (puff topography) is collected during the two
smoking bouts (10 directed puffs per bout, 30 s interpuff
interval) per session using the eTop topography instrument developed and manufactured at the American
University of Beirut (AUB). The AUB research group has
a record of topography instrumentation development
for alternative tobacco products.58 Similar to commercially available cigarette topography instruments, the
Wall CS, et al. BMJ Open 2018;8:e023850. doi:10.1136/bmjopen-2018-023850

instrument senses flow-induced pressure drop across an
orifice incorporated into the mouthpiece. The pressure
drop is sensed by a pressure transducer whose output
voltage every 100 milliseconds is amplified, digitised
and sampled. Specific topography measures of interest
include puff duration, average puff volume, flow rate
and total puff volume inhaled. Mouth pieces for cigars
and cigarettes are individually calibrated prior to each
session to relate puff velocity (mL/s) to the pressure
transducer voltage signal.59 60
Subjective measures
Subjective measures are assessed at nine points during
each session. Subjective measures consist of the shortform of the Addiction Research Centre Inventory
consisting of 49 true–false items,61 the general Labelled
Magnitude Scale for rating flavour intensity,62 the Direct
Effect Scale63 and the Direct Effects of Tobacco Scale.64 65
An additional 12 items are designed to assess tobacco
abstinence symptoms and more general drug effects and
include items like ‘Urges to smoke a cigarette’ and ‘Do
you feel a rush?’. Each of these measures has been used
previously to assess the subjective effects of a variety of
drugs and tobacco products.66–68
Primary outcomes
The primary outcomes of this study include physiological,
behavioural and subjective measures. The primary physiological outcome is saliva nicotine. Primary outcomes for
behavioural measures of abuse liability are breakpoint, elasticity, intensity, Omax and Pmax from the cigarette/cigar
purchase task, cross-price elasticity from the cross-product
purchase task and crossover point from the multiple choice
procedure. Subjective measures predictive of abuse liability,
reinforcing effects and acceptability-related items are used
as the primary subjective outcomes.
Secondary outcomes
The secondary outcome measure is puff topography,
a behavioural measure of smoke inhalation that can be
indicative of toxicant exposure.69 Puff topography data
will be collected during both bouts in each session and
includes puff duration, average puff volume, flow rate
and total puff volume inhaled.
Session timeline
Prior to each session, participants are instructed to
abstain from nicotine/tobacco for at least 12 hours. Abstinence is verified by measuring expired air CO levels at the
beginning of each session. Participants with an expired
air CO reading >10 ppm are considered non-compliant
with abstinence requirements, rescheduled if applicable
and provided an opportunity to comply with session
protocol on another day. Once compliance with the abstinence period is verified, physiological data collection
will begin and participants are instructed to rinse their
mouth with water to remove any food residue and begin a
30 min rest period in order to achieve resting HR and BP
(figure 1). Following the rest period, participants provide
5
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Figure 1 Session timeline in minutes. *, 10 puffs of session
product administered; B, behavioural measures administered;
CO, expired air CO measured; End, physiological monitoring
ends; Phys, physiological monitoring begins and mouth rinse;
S, subjective measures administered; Sal, saliva collection.

a saliva sample, expired air CO is measured and subjective measures are completed.
Product administration begins following completion
of baseline subjective measures. Product administration
consists of 10 directed puffs with a 30 s interpuff interval
and is monitored and recorded using a puff topography
system. There are two product administrations during
each session, with the second occurring 60 min after
the first. The participant completes subjective measures
at 5, 15, 30 and 45 min following each product administration (including baseline, nine times in total). Saliva is
collected 10 min after each product administration and
5 min before the second product administration (four
saliva samples per session). To assess CO boost, expired
air CO concentration is assessed at baseline, 15 min
after each product administration and 5 min before the
second product administration (four CO assessments
each session). HR/BP are recorded throughout the
entire session. Following both product administrations
and completion of all subjective measures, behavioural
task measures are assessed by completion of either one
or two hypothetical purchase tasks (cigarette purchase
task during the own brand cigarette condition; cigar
purchase task and cross-product purchase task during
cigar conditions) as well as the multiple choice procedure for cigarettes in the own brand condition and for
the session-specific cigar in the cigar conditions.
Data monitoring, sample requirements and statistical
analyses
Data and safety monitoring
All baseline questionnaire and subjective response data
are collected at the study site and entered electronically
through the Research Electronic Data Capture system
(REDCap70), a secure database system, hosted at VCU,
and resemble paper forms that received the approval
of the study site IRB. Data quality of participant-entered
forms are monitored by site personnel during all sessions
for completeness, validity and integrity. In the cases where
study personnel observe incomplete or inconsistent
responses, study personnel verify responses with participants and update the electronic record if needed. Data
entered by personnel are checked for accuracy by other
site personnel and detailed item inquiries are recorded
and tracked. Review and modifications are made as
needed, and any information regarding such modifications are recorded and associated with a study staff
6

member based on REDCap user name. Ability to make
such modifications is restricted based on an individual
personnel’s position and privileges. A response to each
inquiry is needed for the queried item to be considered
closed. Data will be monitored for quality purposes every
6 months by the PI and coinvestigator.
While adverse events (AEs; ie, incidents of high BP)
and serious AEs (SAEs; ie, any AE that requires hospitalisation) are not expected, as this protocol is considered
low risk, all research staff who interact with participants
are instructed on procedures involved in managing and
reporting any potential AEs and SAEs. Any AEs or SAEs
are well documented, and these records will be maintained for regular review by the study staff. AEs and SAEs
are monitored during sessions by study staff and assessed
by the researcher for severity and expectedness/relatedness to the study. All documented AEs are reviewed by
the PI and coinvestigator within 1 week of occurrence;
SAE documentation is reviewed within 24 hours. Further,
in the case of an SAE, the medical monitor also is notified and consulted. All AEs are reported to the study site
IRB as part of an annual report, while all SAEs that are
unexpected and deemed related or possibly related are
reported to the study site IRB within two business days
and to the study sponsor within 72 hours.
Sample size
This study will recruit 25 young adults 18–25 years of
age. This number was necessary to detect moderate within-subjects effects (ie, f=0.35) with power >0.80 between
conditions for the primary outcome measures, assuming
a moderate correlation between measures (r>0.50).
Quantitative analyses
Following data cleaning and preparation, linear mixed-effect models including two within-subject factors (condition and time) will be used to assess the condition effect
on the physiological (saliva nicotine), behavioural (crossover point, breakpoint, elasticity, intensity, Omax, Pmax
and cross-price elasticity) and subjective effect outcomes.
Mixed-effect logistic or linear models will be fit to the
data depending on the distribution of the error term.
All models use an independent covariance matrix and
estimate robust standard errors. Predicted probabilities
(logistic mixed-effects models) and predicted values
(linear mixed models) for condition effects will be estimated with bootstrapped CI. We will also test for jointly
significant condition effects across models of physiological, behavioural choice task and subjective measures
of abuse liability. Secondary outcomes (CO, HR, BP,
average puff volume, puff duration, flow rate and total
puff volume) will be analysed similarly. All analyses will be
performed in Stata V.15.

Ethical considerations and dissemination
Ethics approval was granted. All personnel were trained
on study procedures, conducting research with human
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subjects and data safety and monitoring protocols. This
study was funded by the National Institute on Drug Abuse
of the National Institutes of Health and the Food and Drug
Administration (1R03DA043005) and was registered at
ClinicalTrials.gov with protocol number NCT0237051.
Dissemination channels for study findings will include
publishing in the scientific literature, presentations at
scientific meetings and a policy brief to communicate the
implications of the study’s findings to policymakers and
communities.
Study status
Study recruitment began in March 2017. The target sample
size is n=25. As of the time of this submission (April 2018),
30 participants have been consented, 12 failed in-person
eligibility screening, three have withdrawn, one is currently
enrolled and 14 have completed the study. Recruitment is
expected to be completed by May 2018.
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